

ASSOCIATION BEC 22 CENTRE INVESTIGATEUR CARIO-HPCA

LISTE DES PUBLICATIONS SCIENTIFIQUES ESSAIS CLINIQUES REALISES DEPUIS 2002

CANCER DU SEIN

Essais cliniques publiés, investigateur signataire :

Essai Taxotère-Caelyx : Phase I study of pegylated liposomal doxorubicin (CA) and docetaxel (T) bimonthly in the first-line treatment of metastatic breast cancer (MBC) : The CAT regimen.

J-P. Guastalla, **A.C. Hardy-Bessard**, J.-F. Geay, H. Cure, I. Ray-Coquard, D. Paraiso, E. Pujade-Lauraine; Gineco, Paris, France.

American Society of Clinical Oncology, June 2004, New Orleans USA. Poster.

Essai CAPYTOLLE : Docetaxel and liposomal pegylated doxorubicin in metastatic breast cancer patients : the French GINECO group experience.

J.P. Guastalla, R. Largillier, J.F. Geay, **A. C. Hardy Bessard**, S. Kircher, B. Slama, J. Cretin, H. Orfeuvre, Y. Goubely, E. Pujade-Lauraine.

American Society of Clinical Oncology, June 2006, Atlanta USA. Poster

Essai TAXEL : Weekly paclitaxel and capecitabine in HER2-negative metastatic breast cancer (MBC): A multicenter GINECO randomized phase II comparing two paclitaxel-capecitabine schedules.

A. Lortholary, **A. C. Hardy-Bessard**, T. Bachelot, P. Dalivoust, G. de Rauglaudre, J. Alexandre, H. Bourgeois, D. Jaubert, D. Paraiso, R. Largillier; Gineco Group, Paris, France

J Clin Oncol 27:15s, 2009 (suppl; abstr 1114)

Essai PACS 04 : Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, **Hardy-Bessard AC**, Coudert B, Maerevoet M, Piot, G, Kramar A, Martin AL, Penault-Llorca F.

J Clin Oncol. 2009 Dec 20; 27(36):6129-34. Epub 2009 Nov 16.

Essai CAPYTOLLE : Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients : results of the phase II GINECO trial CAPYTTOLE.

de la Fouchardière C, Largillier R, Goubely Y, **Hardy-Bessard AC**, Slama B, Cretin J, Orfeuvre H, Paraiso D, Bachelot T, Pujade-Lauraine E.

Ann Oncol. 2009 Dec; 20(12):1959-63. Epub 2009 Jun 25

Essai TAXEL : Weekly paclitaxel (Ta) and capecitabine (Xe) in HER2-negative metastatic breast cancer (MBC): A multicenter GINECO randomised phase II comparing two Taxel-schedules.

A. Lortholary, **A. C. Hardy-Bessard**, T. Bachelot, P. Dalivoust, G. de Rauglaudre, J. Alexandre, H. Bourgeois, D. Jaubert, D. Paraiso, R. Largillier; Gineco Group, Paris, France

Poster ASCO 2009 (article sous presse)

Essai TAXEL : A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

Lortholary A, **Hardy-Bessard AC**, Bachelot T, de Rauglaudre G, Alexandre J, Bourgeois H, Jaubert D, Paraiso D, Largillier R. *Breast Cancer Res Treat*. 2011 Sep 24.

Stratégie thérapeutique : Node negative breast cancer. Beyond international consensus : a pragmatic approach.

Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-Bessard AC, Jacot W, Misset JL, Nabholz JM, Petit T, Spielmann M, Namer M.
Bull Cancer. 2011 Jul;98(7):807-25. French.

Essai ATHENA : Tolérance et efficacité du bévacicumab en association aux taxanes en première ligne dans le cancer du sein métastatique

Anne-Claire Hardy-Bessard, Rémy Delva, Xavier Pivot, Marc Espié, Florence Dalenc, Marie-Aude Coulon Sfairi, Alain Monnier, Daniel Serin, Corinne Veyret, Alain Lortholary, Maria Pavlyuk, Leila Kockler, Jean-Yves Pierga.
Bull Cancer. 2012 ; 99 : 609-18.

Essai COCCULINE : Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.

Pérol D, Provençal J, Hardy-Bessard AC, Coeffic D, Jacquin JP, Agostini C, Bachelot T, Guastalla JP, Pivot X, Martin JP, Bajard A, Ray-Coquard I.
BMC Cancer. 2012 Dec 17;12(1):603.

Essai DOGMES : Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO.

Sostelly A, Henin E, Chauvenet L, Hardy-Bessard AC, Jestin-Le Tallec V, Kirsher S, Leyronnas C, Ligeza-Poisson C, Ramdane S, Salavt J, Van-Hult S, Vannetzel JM, Freyer G, Tod M, Falandry C.
J Geriatr Oncol. 2013 Jan;4(1):48-57.

Essai PHARE : 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; **PHARE trial investigators**.

Lancet Oncol. 2013 Jul;14(8):741-8.

Essai ATHENA : Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France].

Pierga JY, Delva R, Pivot X, Espié M, Dalenc F, Serin D, Veyret C, Lortholary A, Gligorov J, Joly K, Hernandez J, Hardy-Bessard AC.

Bull Cancer. 2014 Sep;101(9):780-8. doi: 10.1684/bdc.2014.2019.

Essai BEVERLY 1 : Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Bertucci F, Fekih M, Autret A, Petit T, Dalenc F, Levy C, Romieu G, Bonnetterre J, Ferrero JM, Kerbrat P, Soulie P, Mouret-Reynier MA, Bachelot T, Lerebours F, Eymard JC, Deblock M, Lortholary A, Hardy-Bessard AC, Barthelemy P, Bonnefoi H, Charafe-Jauffret E, Bidard FC, Viens P, Lemonnier J, Pierga JY.

Lancet Oncol. 2016 Mar 28. pii: S1470-2045(16)00011-5.

Essai A-TAXEL : Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.

Ferrero JM, Hardy-Bessard AC, Capitain O, Lortholary A, Salles B, Follana P, Herve R, Deblock M, Dauba J, Atlassi M, Largillier R.

Cancer. 2016 Oct 15;122(20):3119-3126. doi: 10.1002/cncr.30170.

Divers : Breast cancer screening: On our way to the future.

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Lorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG).

Bull Cancer. 2016 Sep;103(9):753-63. doi: 10.1016/j.bulcan.2016.06.005.

Divers : Erratum to : "Breast cancer screening : On our way to the future" [Bull. Cancer 103 (2016) 753-763].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG).

Bull Cancer. 2016 Oct 28. pii: S0007-4551(16)30276-4. doi: 10.1016/j.bulcan.2016.10.009.

Essais cliniques publiés, investigateur non signataire :

Essai ALLOS RSR13-RT016 : Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases.

Scott C, Suh J, Stea B, Nabib A, Hackman J.
Am J Clin Oncol. 2007 Dec ; 30(6) : 580-7.

Essai BEVERLY 2 : Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER-2-positive breast cancer (BEVERLY 2) : an open-label, single-arm phase 2 study.

Jean-Yves Pierga, Thierry Petit, Thierry Delozier, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roché, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Maria Pavlyuk, Sandrine Kraemer, François-Clément Bidard, Patricia Viens.

The Lancet oncology/ 28 fev 2012 – 10.1016/S1470-2045.

Essai REBOND : Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min : a randomised, open-label study

Von Moos R, Caspar CB, Thürlimann B, Angst R, Inauen R, Greil R, Bergstrom B, Schmieding K, Pecherstorfer M.
Ann Oncol. 2008 Jul ; 19(7) : 1266-70. *Epub* 2008 Mar 11.

Essai CELAROM : Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients : a double-blind phase III GINECO study.

Falandry C, Debled M, Bachelot T, Delozier T, Cretin J, Romestaing P, Mille D, You B, Mauriac L, Pujade-Lauraine E, Freyer G.
Breast Cancer Res Treat. 2009 Aug ; 116(3) : 501-8. *Epub* 2008 Nov 20

Essai e-ZOFAST : Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.

Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL.

Breast Cancer Res Treat. 2009 Oct ; 117 (3) : 603-9. *Epub* 2009 Feb 12.

Essai ATOLL : Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer : the ATOLL (articular tolerance of letrozole) study.

Briot K, Tubiana-Hulin M, Bastit L, Kloos L, Roux C.

Breast Cancer Res Treat. 2010 Feb ; 120 (1) : 127-34. *Epub* 2009 Dec 25.

Essai TEAM : Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.

Van Nes JG, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJ; Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trialists, Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Hozumi Y, Kerin MJ, Kieback DG, Meershoek-Klein Kranenbarg WM, Hille ET, Nortier JW.

Br J Surg. 2010 May;97(5):671-9.

Essai CA 163-046 : Randomised phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Preze Manga G, Peck R, Poulart V, Conte P.

J Clin Oncol. 2010 Jul 10 ; 28 (20) : 3256-63. *Epub* 2010 Jun 7.

Essai TEAM : Adjuvant tamoxifen and exemestane in early breast cancer (TEAM) : a randomised phase 3 trial.

Van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE.

Lancet. 2011 Jan 22;377(9762):321-31.

Essai ATHENA : First line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer : safety and efficacy in an open-label study in 2,521 patients.

Smith IE, Pierga JY, Biganzoli L, Cortes-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stoyakovskiy D, Francke FA, Kaufman B, Mainwaring P, pienkowski T, De Valk B, Kwong A; Gonzales-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI, ATHENA Study Group.

Ann Oncol. 2011 Mar ; 22 (3) : 595-602. *Epub* 2010 Sep 5.

Essai ATHENA : First-line bevacizumab-containing therapy for breast cancer : results in patients aged ≥ 70 years treated in the ATHENA Study.

Biganzoli L, Di Vincenzo E, Jiang Z, Lichinitser M, Shen Z, Delva R, Bogdanova N, Vivanco GL, Chen Z, Chen Y, Just M, Espi  M, Vinhloes J, Hamm C, Crivellari D, Chmielowska E, Semiglazov V, Dalenc F, Smith I.
Ann Oncol. 2011 Mar 28

Essai EMBRACE : Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE) : a phase 3 open-label randomised study.

Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Di ras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C ; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) Investigators.
Lancet. 2011 Mar 12 ; 377 (9769) : 914-23. *Epub* 2011 Mar 2.

Essai REBOND : Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.

Pivot X, Lortholary A, Abadie-Lacourtois S, Mefti-Lacheraf F, Pujade-Lauraine E, Lefeuvre C, Letessier S, Morvan P, D r C, Frimat L.
Breast. 2011 Dec;20(6):510-4.

Essai BEVERLY 2 : Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT), and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC)

P.Viens, J.Pierga, T.Petit, T. Delozier, J.Ferrero, M.Campone, J.Gligoroc, F.Lerebours, H.Roche, M.Pavlyuk, T.D.Bachelot, E. Charafe-Jauffret
2011 ASCO Annual Meeting ; *J.Clin. oncol.* 29 : 2011 (suppl, abstr 531)

Essai prospectif de phase II : complication post-op ratoires dans le cadre d'un traitement n oadjuvant incluant le bevacizumab dans le cancer du sein inflammatoire (CSI) HER2 positif

R.Rouzier, E.Lambaudie, J.Y.Pierga, T.Petit, T.Delozier, JM.Ferrero, M.Campone, J.Gligorov, F.Lerebours, H.Roch , D.Pau, P.Viens, RJ Salmon.
2011 ASCO Annual Meeting ; *J.Clin. oncol.* 29 : 2011 (suppl, abstr 569)

Essai BEVERLY 2 : Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.

Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roch  H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P.
Lancet Oncol. 2012 Apr;13(4):375-84.

Essai EMBRACE : A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.

Lopes G, Gl ck S, Avancha K, Montero AJ.
Breast Cancer Res Treat. 2013 Jan;137(1):187-93.

Essai PACS 04 : Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.

Roca L, Di ras V, Roch  H, Lappartient E, Kerbrat P, Cany L, Chieze S, Canon JL, Spielmann M, Penault-Llorca F, Martin AL, Mesleard C, Lemonnier J, de Cremoux P.
Breast Cancer Res Treat. 2013 Jun;139(3):789-800.

Essai TEAM : Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.

Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, Kranenbarg EM, Hasenburg A, Paridaens RJ, Vannetzel JM, Markopoulos C, Hozumi Y, Bartlett JM, Jones SE, Rea DW, Nortier JW, van de Velde CJ.
J Clin Oncol. 2013 Jun 20;31(18):2257-64.

Essai PHARE : 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators.
Lancet Oncol. 2013 Jul;14(8):741-8.

Essai DOGMES : Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.

Falandry C, Brain E, Bonnefoy M, Mefti F, Jovenin N, Rigal O, Guillem O, El Kouri C, Uwer L, Abadie-Lacourtoisie S, Cretin J, Jacquin JP, Paraiso D, Freyer G.
Eur J Cancer. 2013 Sep;49(13):2806-14.

Essai ALTTO : Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G.
Breast Cancer Res Treat. 2014 Feb;143(3):485-92.

Essai PHARE : Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.

Kramar A¹, Bachelot T², Madrange N³, Pierga JY⁴, Kerbrat P⁵, Espié M⁶, Fumoleau P⁷, Pauporté I⁸, Khayat D⁹, Romieu G¹⁰, Pivot X¹¹.
Ann Oncol. 2014 May 14. pii: mdu177.

Essai BOLERO 3 : Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L.
Lancet Oncol. 2014 May;15(6):580-91.

Essai CARIATIDE : The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the Compliance of ARomatase Inhibitors AssessmentT In Daily practice through Educational approach (CARIATIDE) study.

Neven P¹, Markopoulos C², Tanner M³, Marty M⁴, Kreienberg R⁵, Atkins L⁶, Franquet A⁷, Gnant M⁸, Neciosup S⁹, Tesarova P¹⁰, Barni S¹¹, Deschamp V¹².
Breast. 2014 Aug;23(4):393-9. doi: 10.1016/j.breast.2014.02.009. Epub 2014 Mar 24.

Essai PHARE : Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.

Pivot X, Suter T, Nabholz JM, Pierga JY, Espie M, Lortholary A, Khayat D, Pauporte I, Romieu G, Kramar A, Fumoleau P.
Eur J Cancer. 2015 Sep;51(13):1660-6.

Essai ALTTO : Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart M, Azim HA Jr.
J Natl Cancer Inst. 2016 Apr 20;108(8). pii: djw037.

Essai BOLERO-3 : Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D.
J Clin Oncol. 2016 Jun 20;34(18):2115-24

Essai A-TAXEL : Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.

Ferrero JM, Hardy-Bessard AC, Capitain O, Lortholary A, Salles B, Follana P, Herve R, Deblock M, Dauba J, Atlissi M, Largillier R.
Cancer. 2016 Oct 15;122(20):3119-3126. doi: 10.1002/cncr.30170.

CANCERS DE L'OVAIRE, ENDOMETRE ET COL

Essais cliniques publiés, investigateur signataire :

Essai ELOGEM : Gemcitabine and Oxaliplatin in patients with recurrent advanced ovarian cancer in early progression (< 6 months) : a GINECO phase II trial. .

N. Dohollou, B. Weber, J.F. Geay, **A.C. Hardy-Bessard**, E. Levy, B. Chauffert, J. Cretin, H. Orfeuvre, D. Paraiso, E. Pujade-Lauraine, GINECO

American Society of Clinical Oncology, May-June 2003, Chicago USA. Poster

Essai HYPAR : combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer : a GINECO phase I-II trial.

Kurtz JE, Freyer G, Joly F, Gladiéff L, Kaminski MC, Fabbro M, , **A.C. Hardy-Bessard**, Raban N, Ray-Coquard I, Pujade-Lauraine E, GINECO group. France.

Anticancer Res; 2012 Mar ; 32(3) : 1045-9.

Essai TC-HERCEPTIN :HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group.

S. Camilleri-Broet, **A.C. Hardy-Bessard**, A. Letourneau, D. Paraiso, O. Levrel, B. Leduc, S. Bain, H. Orfeuvre, J. Audouin, E. Pujade-Lauraine, GINECO group.

Ann Oncol. 2004 Jan;15(1):104-12.

Essai TC-TOP : Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer : A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

J. Pfisterer, B. Weber, A. Reuss, R. Kimming, A. Du Bois, U. Wagner, H. Bourgeois, W. Meier, S. Costa, J. Blohmer, A. Lortholary, S. Olbricht, A. Stähle, C. Jackisch, **A. C. Hardy Bessard**, V. Möbus, J. Quaas, B. Richter, W. Schröder, J. F. Geay, H. J. Lück, W. Kuhn, H. Meden, U. Nitz, E. Pujade-Lauraine.

Journ of the National Cancer Institute, August 2006 ; 98 (15) : 1036-45.

Essai ELOGEM : Gemcitabin-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment : a phase II study from the GINECO group.

Ray-Coquard I, Weber B, Cretin J, Haddad-Guichard Z, Lévy E, **Hardy-Bessard AC**, Gouttebel MC, Geay JF, Aleba A, Orfeuvre H, Agostini C, Provencal J, Ferrero JM, Fric D, Dohollou N, Paraiso D, Salvat J, Pujade-Lauraine E; GINECO group.

Br J Cancer. 2009 Feb 24;100(4):601-7.

Essai ERBUS : Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.

Kurtz JE, **Hardy-Bessard AC**, Deslandres M, Lavau-Denes S, Largillier R, Roemer-Becuwe C, Weber B, Guillemet C, Paraiso D, Pujade-Lauraine E.

Gynecol Oncol. 2009 Feb 14.

Essai TCG : Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.

Du Bois A, Herrstedt J, **Hardy-Bessard AC**, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehoul J.

J Clin Oncol. 2010 Sep 20;28(27):4162-9. Epub 2010 Aug 23.

Essai HYPAR : Combined Oral Topotecan plus Carboplatin in Relapsed or Advanced Cervical Cancer: A GINECO Phase I-II Trial.

Kurtz JE, Freyer G, Joly F, Gladiéff L, Kaminski MC, Fabbro M, Floquet A, **Hardy-Bessard AC**, Raban N, Ray-Coquard I, Pujade-Lauraine E; ON BEHALF OF THE GINECO GROUP, FRANCE.

Anticancer Res. 2012 Mar;32(3):1045-1049.

Essai CALYPSO : Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.

Lee CK, Lord S, Grunewald T, GebSKI V, **Hardy-Bessard AC**, Sehoul J, Woie K, Heywood M, Schauer C, Vergote I, Scambia G, Ferrero A, Harter P, Pujade-Lauraine E, Friedlander M.

Gynecol Oncol. 2015 Jan;136(1):18-24. doi: 10.1016/j.ygyno.2014.09.017. Epub 2014 Oct 2.

Essai TARCEVA : Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varela-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG).; Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO).; Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO).; National Cancer Research Institute (NCRI).; Australia New Zealand Gynaecological Oncology Group (ANZGOG).; Mario Negri Gynecologic Oncology group (MaNGO)..
Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6. Erratum in: *Target Oncol.* 2016

Divers : Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.

Colombo N, **Hardy-Bessard AC**, Ferrandina G, Marth C, Romero I.
Expert Rev Anticancer Ther. 2016 Nov;16(sup1):11-19.

Essais cliniques publiés, investigateur non signataire :

Essai ET-743-INT 11 : A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.

Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME.
Br J Cancer. 2007 Dec 17; 97 (12) : 1618-24. Epub 2010 Aug 23.

Essai TC-HERCEPTIN : HER2 Overexpression / Amplification and Trastuzumab Treatment in Advanced Ovarian Cancer : A GINECO Phase II Study.

Isabelle Ray-Coquard, Jean-Paul Guastalla, Djelila Allouache, Martin Combe, Béatrice Weber, J.Crétin, Hervé Curé, S.Nunhuck, Désiré Paraiso, Mireille Mousseau, Ris Pujade-Lauraine on behalf of GINECO, France.
Clinical Ovarian Cancer, Juin 2008

Essai ELOGEM : Gemcitabin-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment : a phase II study from the GINECO group.

Ray-Coquard I, Weber B, Cretin J, Haddad-Guichard Z, Lévy E, **Hardy-Bessard AC**, Gouttebel MC, Geay JF, Aleba A, Orfeuvre H, Agostini C, Provencal J, Ferrero JM, Fric D, Dohollou N, Paraiso D, Salvat J, Pujade-Lauraine E; GINECO group.
Br J Cancer. 2009 Feb 24;100(4):601-7.

Essai PACA : Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer : a GINECO group phase II trial.

Weber B, Lortholary A, Mayer F, Bourgeois H, Orfeuvre H, Combe M, Platini C, Cretin J, Fric D, Paraiso D, Pujade-Lauraine E.
Anticancer Res. 2009 Oct ; 29 (10) : 4195-200.

Essai CALYPSO : Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Pujade-Lauraine E, Wagne U, Aavall-Lundqvist E, GebSKI V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, Du Bois A.
J Clin Oncol. 2010 Jul 10 ; 28 (20) : 3323-9. Epub 2010 May 24.

Essai CARTAXHY : Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer : the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)

Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, Slama B, Dauba J, Paraiso D, Pujade-Lauraine E, on behalf of the GINECO group, France.
Ann Oncol. 2011 May 11.

Essai CALYPSO : Ovarian cancer in elderly patients : carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse : a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E, on behalf of Gynecologic Cancer Intergroup.
Ann Oncol. 2011 Nov;22(11):2417-23.

ESSAI CALYPSO : Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination ; Analysis from the GCIG CALYPSO relapsing ovarian cancer trial.

Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M, Reinthaller A, Vergot I, Ferrandina G, Dell'Anna T, Huober J, Pujade-Lauraine E.
Gynecol Oncol. 2011 Aug;122(2):226-32.

Essai ICON 7 : A phase 3 trial of bevacizumab in ovarian cancer.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators.
N Engl J Med. 2011 Dec 29;365(26):2484-96.

Essai CALYPSO : CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.

Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E.
Br J Cancer. 2012 Feb 14;106(4):633-7.

Essai CALYPSO : Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S.
Ann Oncol. 2012 May;23(5):1185-9.

Essai CALYPSO : Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.

Brundage M, Gropp M, Mefti F, Mann K, Lund B, GebSKI V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E.
Ann Oncol. 2012 Aug;23(8):2020-7.

Essai CALYPSO : Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.

Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, GebSKI V, Lauraine EP.
Br J Cancer. 2012 Aug 7;107(4):588-91

Essai ICON 7 : Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.

Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T.
Lancet Oncol. 2013 Mar;14(3):236-43.

Essai ENDORAD : Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

Ray-Coquard I, Favier L, Weber B, Roemer-Becuwe C, Bougnoux P, Fabbro M, Floquet A, Joly F, Plantade A, Paraiso D, Pujade-Lauraine E.
Br J Cancer. 2013 May 14;108(9):1771-7.

Essai CALYPSO : The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).

You B, Colombari O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A.
Gynecol Oncol. 2013 Aug;130(2):289-94.

Essai TARCEVA : Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platinum-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despiere E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.
J Clin Oncol. 2014 Feb 1;32(4):320-6.

Essai MITO 7 : Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7) : a randomised, multicentre, open-label, phase 3 trial.

Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutati V, Ricci C, Pisano C, Gregg S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIg) Investigators.
Lancet Oncol. 2014 Apr;15(4):396-405.

Essai AURELIA : Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freuden sprung U, Sneller V, Hales G, Pujade-Lauraine E.
J Clin Oncol. 2014 May 1;32(13):1309-16.

Essai AURELIA : Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.
J Clin Oncol. 2014 May 1;32(13):1302-8.

Essai REV : A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.

Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, Fabbro M, Lesoin A, Lortholary A, Pujade-Lauraine E.
Ann Oncol. 2014 Sep 10. pii: mdu392.

Essai ICON 7 : Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators.
Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.

Essai ICON 7 : Discordance between the results and conclusions of ICON7.

Gyawali B, Shimokata T, Ando Y.
Lancet Oncol. 2015 Oct;16(13):e478.

Essai ICON 7 : Discordance between the results and conclusions of ICON7 - Authors' reply.

Oza AM, Cook AD, Kaplan R, Parmar MK, Perren TJ; ICON7 investigators.
Lancet Oncol. 2015 Oct;16(13):e478-9.

Essai OVAR 12 : Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium.
Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6

Essai AURELIA : Independent Radiologic Review of AURELIA, A Phase 3 Trial of Bevacizumab Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer.

Husain A, Wang Y, Hanker LC, Ojeda B, Anttila M, Breda E, Vuylsteke P, Pujade-Lauraine E.
Gynecol Oncol. 2016 May 13

Essai AURELIA : Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.

Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladiéff L, Sehouli J, Khoon Lee C, GebSKI V, Pujade-Lauraine E.
Ann Oncol. 2016 Jun 10.

CANCERS DIGESTIFS

Essais cliniques publiés, investigateur signataire :

Essai FFCD 2000-05 : Essai de stratégie de chimiothérapie des tumeurs colorectales métastatiques (FFCD 2000-05) : résultats préliminaires de toxicité et d'observance

Castaing M., Bouché O., **Etienne PL.**, Texereau P., Auby D., Bedenne L., Rougier P., Gargot D., Azzedine A., Gasmi M., Abbas M., Ducreux M., pour les investigateurs de l'essai FFCD 2000-05.
Gastroenterol. Clin Bio 2005 ; 29 : A80.

Essai FFCD 9710 : Preliminary results of a randomized phase III trial comparing streptozotocin plus fluorouracil versus interferon for metastatic carcinoid tumors (FNCLCC - FFCD 9710).

J. F. Seitz, L. Dahan, P. Rougier, J. L. Raoul, E. Gamelin, **P. L. Etienne**, G. Cadiot, D. Smith, F. Ricard, F. Bonnetain.
Proc ASCO 2006 ; 24 : 4090.

Essai FFCD 2000-05 : Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): Preliminary results.

O. Bouché, M. Castaing, **P. L. Etienne**, P. Texereau, D. Aubry, L. Bedenne, P. Rougier, D. Gargot, M. Gasmi, M. Ducreux.
Proc ASCO 2007 ; 25 : 4069.

Essai FFCD 9710 : Essai de phase III comparant une chimiothérapie par 5-FU + Steptozotocine à une immunothérapie par interferon alpha2-a recombinant dans le traitement des tumeurs carcinoïdes métastatiques avancées (FNCLCC-FFCD 9710).

L Dahan, E Mitry, F Bonnetain, JL Raoul, E Gamelin, **PL Etienne**, G Cadiot, D Smith, F Ricard, P Rougier, JF Seitz .
Gastroenterol Clin Biol. 2007 Mar; 31(HSII):A107.

Essai L9326 : Randomized phase II study of chemotherapy (CRT) comparing Folfox 4 versus 5FU-csiplatin in first line treatment of patients with inoperable oesophageal cancer (IEC).

A.ADENIS, **PL.ETIENNE**, P.MICHEL, JY.DOUILLARD, JL.RAOU, L.MINEUR, M.RIVES, D.PEIFFERT, Y.YATAGHENE, T.CONROY
Gastro-intestinal Cancer Symposium 2007 – Orlando 19-21 jan. Abs.

Essai FFCD 2000-05 : Etudes statistiques complémentaires de l'essai stratégique FFCD 2000-05 : une monochimiothérapie d'emblée ne fait pas courir de risque au patients ayant un cancer colorectal métastaté.

J Pénichou, M Ducreux, O Bouché, **PL Etienne**, P Texereau, D Auby, L Bedenne, P Rougier, JP Pignon, D Gargot, M Gasmi, S Michiels.
Gastroenterol Clin biol., 2009 Mar ; 33 (HSI) : CO136.

Essai ACCORD 12 : Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2.

J. Gérard, D. Azria, S. Gourgou-Bourgade, I. Martel-Laffay, C. Hennequin, **P. Etienne**, V. Vendrely, T. Conroy, E. Francois, C.
J Clin Oncol 27:18s, 2009 (suppl; abstr LBA4007)

Essai FFCD 0504 : Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/ UGT1A1*1 or UGT1A1*1/ UGT1A1*28 (FFCD 0504). Results of a planned interim analysis

E. Mitry, O. Bouché, L. Dahan, F. Bonnetain, P. Laurent-Puig, T. Aparicio, **P. L. Etienne**, C. Lecaille, J. P. Lafargue, Fédération Francophone de Cancérologie Digestive (FFCD), J. L. Jouve.
J Clin Oncol 27:15s, 2009 (suppl; abstr 4065) trial..

Essai FFCD 9710 : Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.

Dahan L, Bonnetain F, Rougier P, Raoul JL, Gamelin E, **Etienne PL**, Cadiot G, Mitry E, Smith D, Cvitkovic F, Coudert B, Ricard F, Bedenne L, Seitz JF; Fédération Francophone de Cancérologie Digestive (FFCD); Digestive Tumors Group of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).
Endocr Relat Cancer. 2009 Dec;16(4):1351-61. Epub 2009 Sep 2.

Essai ACCORD 12 : Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, **Etienne PL**, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T. *Comment in: J Clin Oncol. 2010 Apr 1;28(10):1623-4. // J Clin Oncol. 2010 Oct 10;28(29):e577-8; author reply e581-3.*

Essai L9326 : Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer.

Conroy T, Yataghène Y, **Etienne PL**, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Lamezec B, Rio E, Le Prisé E, Peiffert D, Adenis A. *Br J Cancer. 2010 Oct 26;103(9):1349-55. Epub 2010 Oct 12.*

Essai FFCD 2000-05 : Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial.

Michel Ducreux, David Malka, Jean Mendiboure, **Pierre-Luc Etienne**, Patrick Texereau, Dominique Auby, Philippe Rougier, Mohamed Gasmi, Marine Castaing, Moncef Abbas, Pierre Michel, Dany Gargot, Ahmed Azzedine, Catherine Lombard-Bohas, Patrick Geoffroy, Bernard Denis, Jean-Pierre Pignon, Laurent Bedenne*, Olivier Bouché*, for the Fédération Francophone de Cancérologie Digestive (FFCD) 2000–05 Collaborative Group

The Lancet oncology September 7, 2011

Essai ACCORD 12 : Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, **Etienne PL**, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Seitz JF, Bedenne L, Juzyna B, Conroy T.

J Clin Oncol. 2012 Dec 20;30(36):4558-65. doi: 10.1200/JCO.2012.42.8771. Epub 2012 Oct 29.

Essai ACCORD 12 : Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer : the French randomised trial ACCORD12/0405 PRODIGE 2.

Rullier A, Gourgou-Bourgade S, Jarlier M, Bibeau F, Chassagne-Clément C, Hennequin C, **Tisseau L**, Leroux A, Ettore F, Peoc'h M, Diebold MA, Robin YM, Kleinclauss I, Mineur L, Petitjean C, Mosnier JF, Soubeyran I, Padilla N, Lemaistre AI, Bérille J, Denis B, Conroy T, Gérard JP.

Eur J Cancer. 2013 Jan ; 49(1):82-9.

ESSAI FFCD 2000-05 : Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.

Pénichoux J, Michiels S, Bouché O, **Etienne PL**, Texereau P, Auby D, Rougier P, Ducreux M, Pignon JF.

Eur J Cancer. 2013 Mar 11. pii: S0959-8049(13)00114-7.

ESSAI PRODIGE 5 / ACCORD 17 : Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, **Etienne PL**, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group.

Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18.

ESSAI PRODIGE 2 / ACCORD 12 : Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.

François E, Azria D, Gourgou-Bourgade S, Jarlier M, Martel-Laffay I, Hennequin C, **Etienne PL**, Vendrely V, Seitz JF, Conroy T, Juzyna B, Gerard JP.

Radiother Oncol. 2014 Jan;110(1):144-9. doi: 10.1016/j.radonc.2013.10.019. Epub 2014 Jan 10.

Essai FFCD 0307 : Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.

Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, André T, Gornet JM, Aparicio T, Nguyen S, Azzedine A, **Etienne PL**, Boucher E, Rebischung C, Hammel P, Rougier P, Bedenne L, Bouché O.

J Clin Oncol. 2014 Nov 1;32(31):3520-6.

Essai FFCD 0504 : High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.

Manfredi S¹, Bouché O², Rougier P³, Dahan L⁴, Llorca MA³, Aparicio T⁵, Etienne PL⁶, Lafargue JP⁷, Lécaille C⁸, Legoux JL⁹, Le Malicot K¹⁰, Maillard E¹⁰, Lecomte T¹¹, Khemissa F¹², Breysacher G¹³, Michel P¹⁴, Mity E¹⁵, Bedenne L¹⁶.
Mol Cancer Ther. 2015 Oct 22.

Essai E-DIS-1006 : First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control.

Kotecki N, Huret S, **Etienne PL**, Penel N, Tresch E, François E, Galais MP, Ben Abdelghani M, Michel P, Dahan L, Ghiringelli F, Bedenne L, Samalin E, Piessen G, Bennouna J, Peugniez C, El Hajbi F, Clisant S, Kramar A, Mariette C, Adenis A.
Oncology. 2016;90(2):88-96. doi: 10.1159/000442947.

Essai REBECCA : Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.

Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, Dourthe LM, **Etienne PL**, Mineur L, Clisant S, Phelip JM, Kramar A, Andre T.
BMC Cancer. 2016 Jul 7;16:412. doi: 10.1186/s12885-016-2440-9. Erratum in: *BMC Cancer.* 2016;16(1):518.
Erratum BMC Cancer. 2016 Jul 25;16(1):518.

Essais cliniques publiés, investigateur non signataire :

Essai ACCORD 02 : A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, Viret F, Becouan Y, Bouché O, Gamelin E, Ducreux M, Conroy T, Seitz JF, Bedenne L, Kramar A.
Ann Oncol. 2009 Apr; 20 (4) : 674-80. Epub 2009 Jan 29.

Essai ACCORD 03 : Radiochemotherapy of locally advanced anal canal carcinoma : prospective assessment of early impact on the quality of live (randomised trial ACCORD 03).

Tournier-Rangear L, Mercier M, Peiffert D, Gerard JP, Lemanski C, Romestaing C, Mirabel X, Pommier P, Denis B.
Radiother Oncol. 2008 Jun; 87 (3) : 391-7. Epub 2008 Jan 11.

Essai ACCORD 03 : Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC) : definitive analysis of the intergroup ACCORD 03 trial. 45th annual meeting of the American Society Clinical Oncology.

T Conroy, M. Ducreux, C. Lemanski, et Al.
J Clin Oncol 2009; 27 (18S) Part 1, 176s (Abstr.).

Essai FFCD 0301 : Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer : final results of a randomised strategic phase III trial (FFCD 0301).

Dahan L, Bonnetain F, Ychou M, Mity E, Gasmi M, Raoul JL, Cattan S, Phelip JM, Hammel P, Chauffert B, Michel P, Legoux JL; Rougier P, Bedenne L, Seitz JF; Fédération Francophone de Cancérologie Digestive.
Gut. 2010 Nov; 59 (11) : 1527-34.

Essai ACCORD 11 : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup.
N Engl J Med. 2011 May 12;364(19):1817-25.

Essai ACCORD 03 : Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

Peiffert D, Tournier-Rangear L, Gérard JP, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Luporsi E, Conroy T, Montoto-Grillot C, Mornex F, Lusinchi A, Hannoun-Lévi JM, Seitz JF, Adenis A, Hennequin C, Denis B, Ducreux M.
J Clin Oncol. 2012 Jun 1; 30(16):1941-8.

Essai L9326 : Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.

Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L. *J Clin Oncol*. 2012 Dec 10 ; 30(35):4337-43.

Essai ASPECCT : Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappan S, Sidhu R. *Lancet Oncol*. 2014 May;15(6):569-79.

Essai PETACC 8 : Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C. *Lancet Oncol*. 2014 Jul;15(8):862-73.

Essai ACCORD 12 : Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial.

Gérard JP, Chamorey E, Gourgou-Bourgade S, Benezery K, de Laroche G, Mahé MA, Boige V, Juzyna B. *Radiother Oncol*. 2015 May;115(2):246-52.

Essai FFCD 0307 : Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD_0307).

Nuemi G, Devilliers H, Le Malicot K, Guimbaud R, Lepage C, Quantin C. *Health Qual Life Outcomes*. 2015 Sep 22;13:151.

Essai ACCORD 11 : Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial.

Barbieri A, Anota A, Conroy T, Gourgou-Bourgade S, Juzyna B, Bonnetain F, Lavergne C, Bascoul-Mollevi C. *Med Decis Making*. 2016 Jul;36(5):615-28. doi: 10.1177/0272989X15621883

Essai ADAGE : PRODIGE_34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial.

Aparicio T, Francois E, Cristol-Dalstein L, Carola E, Maillard E, Paillaud E, Retornaz F, Faroux R, André T, Bedenne L, Seitz JF. *Dig Liver Dis*. 2016 Feb;48(2):206-7. doi: 10.1016/j.dld.2015.11.023.

CANCERS DE LA PROSTATE

Essais cliniques publiés, investigateur signataire :

Essai CP 2001 : Multicenter randomized phase II study of two schedules of docetaxel , estramustine and prednisone versus mitoxantrone plus prednisone in patients with hormone-refractory prostate cancer.

S. Oudard, E. Banu, P. Beuzeboc, E. Voog, L. M. Dourthe, **A. C. Hardy Bessard**, C. Linassier, F. Scotte, A. Banu, Y. Coscas, F. Guinet, M.F. Poupon, J.M. Andrieu.
J.Clin.Oncol. 2005 May 20 : 3343-51.

Essai GETUG 15 : Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, **Hasbini A**, Bousquet G, Soulie M.
Lancet Oncol. 2013 Feb;14(2):149-58.

Essai GETUG 15 : Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, **Hasbini A**, Bousquet G, Soulie M, Fizazi K.
Eur J Cancer. 2014 Mar;50(5):953-62.

Essai GETUG-16 : Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fournieret P, Ruffion A, Dussart S.
Lancet Oncol. 2016 Jun;17(6):747-56. doi: 10.1016/S1470-2045(16)00111-X.